The Screening, Diagnostic, Therapy Selection, Minimal Residual Disease and Screening Market Potential are all explored in this report. We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.
Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread cancer screening tests.
The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. What Growth Phase is the market in? The impact on the healthcare industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.
The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.
Make investment decisions and valuations with confidence using the latest data.
The report includes five year market forecasts.
Table of Contents
Companies Mentioned
- Abbott Laboratories
- AccuraGen Inc.
- Acuamark Diagnostics
- Admera Health, LLC
- Agilent
- Amoy Diagnostics Co., Ltd.
- Anchor Dx
- ANGLE plc
- Applied DNA Sciences
- ARUP Laboratories
- AstraZeneca
- Asuragen
- AVIVA Systems Biology
- Bayer
- Baylor Miraca Genetics Laboratories
- Beckman Coulter Diagnostics (Danaher)
- Becton, Dickinson and Company
- Berkley Lights
- BGI Genomics Co. Ltd
- BillionToOne
- Bio-Rad Laboratories, Inc
- Bio-Techne
- Bioarray Genetics
- BioCaptiva
- Biocartis
- Biocept, Inc.
- Biodesix Inc.
- BioFluidica
- Biolidics Ltd
- bioMérieux Diagnostics
- Bioneer Corporation
- Bioview
- Burning Rock
- Cancer Centre
- Cardiff Oncology
- CareDx
- Caris Molecular Diagnostics
- CellCarta
- CellMax Life
- Cepheid (Danaher)
- Circulogene
- Cizzle Biotech
- Cizzle Biotechnology
- Clearbridge Biomedics
- Clinical Genomics
- CorePath Laboratories
- Cytolumina Technologies Corp.
- Datar Cancer Genetics Limited
- Delfi
- Delfi Diagnostics
- Diagnologix LLC
- Dxcover
- Element Biosciences
- Enzo Biochem
- Eone-Diagnomics
- Epic Sciences
- Epigenomics AG
- Eurofins Scientific
- Exact Sciences
- Fluxion Biosciences (Cell Microsystems)
- FoundationOne
- Freenome
- Fyr Diagnostics
- GeneFirst Ltd.
- Genetron Holdings
- GenoMe Diagnostics
- GILUPI Nanomedizin
- Grail
- Guardant Health
- HansaBiomed
- Haystack Oncology
- Haystack Oncology (Quest Dx)
- Hedera
- iCellate
- ICON PLC
- Illumina
- IMBdx
- Incell Dx
- Inivata
- INOVIQ
- Invitae
- Invitae Corporation
- IVBH Bio
- J&J Innovative Medicine
- Lucence Health
- Lunglife AI Inc
- MDNA Life SCIENCES, Inc.
- MDx Health
- MDxHealth
- Menarini
- Menarini Silicon Biosystems
- Mesa Laboratories, Inc.
- Millipore Sigma
- Miltenyi Biotec
- miR Scientific
- Molecular Health
- Myriad Genetics
- Nanostring
- NantHealth, Inc.
- Natera
- Naveris
- NeoGenomics
- Novogene
- On-Chip Biotechnologies
- Oncimmune
- Oncocyte
- OncoDNA
- Oxford Nanopore Technologies
- PamGene
- Panagene
- Personalis
- PGDx (Labcorp)
- Precision Oncology
- PrecisionMed
- Predicine
- Predictive Oncology
- Prenetics
- Promega
- Qiagen
- Rarecells SAS
- RareCyte
- Revvity
- Roche Diagnostics
- Saga Diagnostics
- Screencell
- Siemens Healthineers
- simfo GmbH
- Singlera Genomics Inc.
- Singular Genomics
- Sophia Genetics
- Standard BioTools
- Stilla Technologies
- Superfluid Dx
- Sysmex Inostics
- Tempus Labs, Inc.
- Thermo Fisher Scientific
- Todos Medical
- Ultima Genomics
- Veracyte
- VolitionRX
- Vortex Biosciences